Odyssey Therapeutics Re-files for Nasdaq IPO After Raising $213M in Series D Following Prior Withdrawal

Apr 20, 2026 12:01 CST Updated 12:01

Odyssey Therapeutics

Developer of Immunomodulators and Oncology Drugs

We previously reported on a biotech company that withdrew its IPO due to a weak capital market, only to raise $213 million in private funding after canceling the listing.Odyssey Therapeutics。

And now,After being silent for nearly a year, Odyssey Therapeutics has once again filed an IPO application with the U.S. Securities and Exchange Commission (SEC), planning to go public on Nasdaq under the stock code“ODTX”According to the latest prospectus filed, the company plans to raise $100 million. The underwriters include well-known institutions such as J.P. Morgan, TD Cowen, and Cantor Fitzgerald.

At this re-filing, the market generally believes that the IPO sentiment has warmed up compared to last year, and the financing window for the biotech sector is gradually opening.

The Journey and Pipeline of Odyssey

Odyssey TherapeuticsFounded in 2021, with its headquarters in Boston, the company focuses on developing innovative therapies for autoimmune and inflammatory diseases. Before attempting another IPO, the company completed a $213 million Series D financing round in September 2025, with investors including Affinity Asset, Dimension Capital, Lightspeed Ventures, TPG Life Sciences, and others. The cumulative amount raised in the previous Series A, B, and C rounds reached $487 million.

According to the latest SEC filings, SR One Capital Management holds 10.6% of the company's shares, with OrbiMed and Fidelity also being major shareholders.

The lead project OD-001 is an oral RIPK2 inhibitor,Currently, it hasAchieved proof of concept in the Phase 2a trial for ulcerative colitis, and is currently conducting a Phase 2b monotherapy study and a Phase 2a combination study with vedolizumab.

The company's second project, OD-002, is an oral SLC15A4 inhibitor,Currently inINDApplication Phase, aiming to block nucleic acid-driven TLR7/8/9 signaling, for interferon diseases such as systemic lupus erythematosus and CLE。

In addition, Odyssey is developing OD-003, a VHH-based TNFR2 agonist designed to selectively expand and stabilizeTregCells; OD-004, a bispecific antagonist of TSLP and IL-33 for respiratory diseases; and a small-molecule IRAK4 scaffold inhibitor targeting the myddosome. It is also collaborating with Terray Therapeutics on an IRF5 inhibitor program.

Reference Source:

https://www.tradingview.com/news/tradingview:c46c52d7eb10c:0-odyssey-therapeutics-clinical-stage-immunology-biopharma-files-for-nasdaq-ipo/